TransMedics Group, Inc. — Director's Dealing 2022

Jul 22, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: TransMedics Group, Inc. (TMDX)
CIK: 0001756262
Period of Report: 2022-07-20

Reporting Person: Carey John F (VP of Operations)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-07-20	Common Stock	M	375	$16.14	Acquired	754	Direct
2022-07-20	Common Stock	M	1125	$13.28	Acquired	1879	Direct
2022-07-20	Common Stock	S	1500	$34.57	Disposed	379	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-07-20	Stock Option (Right to Buy)	$16.14	M	375	Disposed	2030-02-27	Common Stock (375)	Direct
2022-07-20	Stock Option (Right to Buy)	$13.28	M	1125	Disposed	2032-02-22	Common Stock (1125)	Direct

Footnotes

F1: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan.

F2: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $34.50 to $34.71, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F3: The option vested and will continue to vest at a rate of 2.0833% of the total number of shares each month until the option is fully vested on the fourth anniversary of the vesting commencement date, February 27, 2020. As of the date of this report, the option remains subject to vesting with respect to 6,250 shares.

F4: The option vested and will continue to vest at a rate of 2.0833% of the total number of shares each month until the option is fully vested on the fourth anniversary of the vesting commencement date, February 22, 2022. As of the date of this report, the option remains subject to vesting with respect to 34,042 shares.